Biogen sees FDA approval of MS drug this month
623395
Biogen Idec Inc. of Cambridge said it is in final discussions with the Food and Drug Administration about its new multiple sclerosis drug Antegren, and expects the drug to be approved by the end of the month.
161433
The U.S. Food and Drug   Administration said on Wednesday it had approved Amgen Inc's   drug Vectibix for the treatment of advanced colon cancer.
88298
Genzyme Corp. on Wednesday said the Food and Drug Administration gave marketing approval for Clolar, its agent aimed at treating children with leukemia who have failed prior therapies.
370199
The federal government has just approved a new medicine for multiple sclerosis that doctors say represents a new treatment approach that will significantly reduce the frequency of disabling episodes.
135618
(National-NBC) Nov. 24, 2004 - The Food and Drug Administration has approved the first drug that specifically targets Multiple Sclerosis.
699552
GlaxoSmithKline Plc , Europe's  biggest drugmaker, is set to seek European Union approval for  its experimental breast cancer drug Tykerb, a spokesman said on  Sunday.
93812
The results from the new clinical trial could increase the chances that the Food and Drug Administration will approve the drug for that use.
182674
Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out.
371520
Biogen Idec Inc. won federal approval for its new anti-multiple sclerosis drug Antegren - the first new treatment for MS patients in eight years.
301333
NEW YORK  - Genzyme Corp. announced  Wednesday that its drug Clolar has been approved by the U.S.  Food and Drug Administration (FDA) for the treatment of  children with difficult or relapsed acute lymphoblastic  leukemia (ALL).
427900
BOSTON  Â Biogen Idec said on Wednesday its fourth-quarter profit rose 84 percent, topping expectations, driven by increased sales of its multiple sclerosis drugs Avonex and Tysabri.
139290
Biogen Idec Inc., the third-biggest US biotechnology company, reported a fourth-quarter profit of $48.4 million, helped by sales of its Avonex and Tysabri multiple-sclerosis treatments. Net income was 14 cents a share compared with a net loss of $990.6 million, or $4.03, a year earlier, the Cambridge company said. Revenue almost doubled to $586 million. Biogen is counting on Tysabri, ...
649663
LOS ANGELES/NEW YORK  - The U.S. Food and Drug   Administration said on Wednesday it had approved Amgen Inc.'s   drug Vectibix for use in colon cancer patients whose tumors   have spread despite chemotherapy treatment.
133355
Biogen Idec Inc. and Elan Corp. said yesterday that they have applied to the Food and Drug Administration for approval to sell Tysabri, a multiple sclerosis drug, to treat patients with Crohn's disease.
692137
Amgen announces data from its top pipeline drug candidate.
587421
Investors kept their eye on makers of generic pharmaceuticals Monday with news that Mylan Laboratories Inc. received Food and Drug Administration approval to market a generic version of a Novartis AG hypertension
768157
Biogen presents at the JPMorgan Healthcare Conference.